Precision BioSciences to Report Third Quarter 2025 Financial Results
Precision BioSciences, a clinical stage gene editing company, will publish financial results for the third quarter 2025 and provide a business update on November 3, 2025.
About Precision BioSciences
Precision BioSciences is a clinical stage gene editing company dedicated to improving life with its novel and proprietary ARCUS genome editing platform.
- Utilizes ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases
- ARCUS nucleases have key capabilities and differentiating characteristics that may enable more intended, defined therapeutic outcomes
Precision BioSciences differs from other technologies in the way it cuts, its smaller size, and its simpler structure.
Author's summary: Precision BioSciences reports Q3 2025 results.
More News
- Stephen A. Smith Questions Why Chris Grier Got Fired Before Mike McDaniel After Dolphins' Embarrassing Loss
- Bam Adebayo's evolution into 'three-level scorer' starts with Heat's new offense
- Riley Green & Ella Langley Notch Second Top 10 Together on Country Airplay Chart
- Bose headphones and earbuds return to all-time lows for Black Friday
- Celebrity-approved Halloween nail ideas for spooky season – Scratch
- NSF Award to Monitor Changes in Alaskan River Ecosystem
- Wemby’s Evolution Is Scary: Spurs Phenom Dominates Again, Leaves Heat Defenders Helpless
- Florence + The Machine Return With Everybody Scream And Irish Concert Dates! | SPIN1038
- 'American Horror Story' Season 13 Features an A-List Actress & a Returning Legend
- Trick or Treat Yourself is The Van Buren's buy-one, get-one ticket deal